Skip NavigationSkip to Content

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase 2b Trial

  1. Author:
    Lee, Sulggi A
    Elliott, Julian H
    McMahon, James
    Hartogenesis, Wendy
    Bumpus, Namandje N
    Lifson, Jeffrey
    Gorelick, Robert
    Bacchetti, Peter
    Deeks, Steven G
    Lewin, Sharon R
    Savic, Radojka M
  2. Author Address

    University of California San Francisco, Department of Medicine, Division of HIV/AIDS., Department of Infectious Diseases, Alfred Hospital and Monash University., Johns Hopkins University, Department of Pharmacology and Molecular Sciences., AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., University of California San Francisco, Department of Epidemiology and Biostatistics., The Peter Doherty Institute for Infection and Immunity, The University of Melbourne., University of California San Francisco, Department of Bioengineering and Therapeutic Sciences.,
    1. Year: 2019
    2. Date: Mar
    3. Epub Date: 2018 08 23
  1. Journal: Clinical pharmacology and therapeutics
    1. 105
    2. 3
    3. Pages: 692-702
  2. Type of Article: Article
  3. ISSN: 0009-9236
  1. Abstract:

    Disulfiram (DSF) was well tolerated and activated viral transcription (cell-associated unspliced [CA-US] and plasma HIV RNA) in a Phase 2 dose-escalation trial in HIV+ antiretroviral therapy (ART)-suppressed participants. Here, we investigated whether exposure to disulfiram and its metabolites predicted these changes in HIV transcription. Participants were administered 500 (N=10), 1000 (N=10), or 2000 (N=10) mg of DSF for 3 consecutive days. Disulfiram and four metabolites were measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Changes in CA-US and plasma HIV RNA were quantified by PCR and analyzed in NONMEM. A seven-compartment pharmacokinetic model demonstrated non-linear elimination kinetics. The fitted median area under the curve values (AUC0-72 ) were 3816, 8386, and 22331 mg*hr/L, respectively. Higher exposure predicted greater increases in CA-US (Emax=78%, AUC50 =1600 mcg*hr/L, P=0.013) but not plasma HIV RNA. These results provide support for further development of disulfiram as an important drug for future HIV cure strategies. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

    See More

External Sources

  1. DOI: 10.1002/cpt.1220
  2. PMID: 30137649
  3. WOS: 000458922600024

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel